Urinary vascular endothelial growth factor concentrations in women undergoing gonadotrophin treatment.
A recently identified cytokine, vascular endothelial growth factor (VEGF, vascular permeability factor) has been implicated in ovarian hyperstimulation syndrome in women undergoing assisted reproduction. We postulate that circulating and urinary VEGF values increase following gonadotrophin stimulation, in parallel with the increased ovarian vascularity. A VEGF radioimmunoassay was developed using iodinated VEGF as tracer, a goat anti-VEGF serum as antiserum and recombinant human VEGF as standard. The specificity of the assay was confirmed by comparing the reverse phase high-performance liquid chromatography (HPLC) pattern of VEGF immunoactivity in urine and urine spiked with recombinant VEGF. Urine was concentrated 5-fold prior to measurement by the radioimmunoassay. VEGF:creatinine ratios in early morning urine samples were used to monitor daily urinary VEGF concentrations based on its high correlation (r = 0.77, P < 0.001) with VEGF concentrations in 24 h urine collections. No diurnal variation in VEGF:creatinine ratios was detected. VEGF:creatinine ratios were determined daily from nine women undergoing gonadotrophin-releasing hormone (GnRH) agonist/gonadotrophin treatment. In a further 16 women, early morning urine samples were collected in the peri-ovulatory period. A significant increase (P < 0.005, n = 25) was observed in VEGF:creatinine ratios following human chorionic gonadotrophin (HCG) administration. VEGF:creatinine ratios correlated poorly (r < 0.34) with plasma oestradiol, follicle number and size. It is concluded that urinary VEGF/creatinine ratios increase following HCG stimulation.
Prince Henry's Institute of Medical Research, Monash Medical Centre, Clayton, Victoria, Australia.
D
D
Robertson
K
K
Selleck
A M
AM
Suikkari
V
V
Hurley
J
J
Moohan
D
D
Healy
D006063:Chorionic Gonadotropin / Q000009:adverse effects* / Q000627:therapeutic use; D002851:Chromatography, High Pressure Liquid; D002940:Circadian Rhythm; D016228:Endothelial Growth Factors / Q000652:urine*; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use; D008222:Lymphokines / Q000652:urine*; D008596:Menotropins / Q000627:therapeutic use; D016471:Ovarian Hyperstimulation Syndrome / Q000652:urine; D011247:Pregnancy; D011863:Radioimmunoassay / Q000706:statistics & numerical data; D011994:Recombinant Proteins; D012680:Sensitivity and Specificity; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D006063:Chorionic Gonadotropin; D016228:Endothelial Growth Factors; D008222:Lymphokines; D011994:Recombinant Proteins; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D008596:Menotropins; D016729:Leuprolide